Tarisai Murefu, a member of HPTN 084 and HPTN 084-01 study protocol teams, is the lead outreach worker with the University of Zimbabwe Clinical Trials Research Centre (UZ-CTRC) in Harare, Zimbabwe.

Dr. Lynda Stranix-Chibanda is co-chair of the HPTN 083-01/HPTN 084-01 sub-studies evaluating long-acting injectable cabotegravir in adolescent populations, a member of the HPTN Adolescent Working Group and research scientific director at the University of Zimbabwe Clinical Trials Research Centre in Harare, Zimbabwe. A pediatrician by training, Dr.

Dr. Harriet Nuwagaba-Biribonwoha, an HPTN 084 and HPTN 104 study team member, is an assistant professor of Epidemiology at Columbia University Mailman School of Public Health, research director at ICAP in Eswatini, and CRS leader at the Eswatini Prevention Center Clinical Research Site (CRS).